Yael Fisher

Yael Fisher

Auto-generated profile, based on publicly available information

Yael Fisher

Department of Pathology, Rambam Health Care Campus, Haifa, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
YFYael Fisher
Yael Fisher
MLMaribel D. Lacambra
Maribel D. Lacambra
SAShahd S. Almohsen
Shahd S. Almohsen
CCChit Chow
Chit Chow
JHJason L. Hornick
Jason L. Hornick
BDBrendan C. Dickson
Brendan C. Dickson

23 February 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
RNRoni Nasser
Roni Nasser
YFYael Fisher
Yael Fisher
AKA Klein
A Klein
Click on the article title to read more.

10 December 2024 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Closed access
YFYael Fisher
Yael Fisher
PSPatrick Shannon
Patrick Shannon
OGOrli Greenberg
Orli Greenberg
DCDavid Chitayat
David Chitayat
KCKaren Chong
Karen Chong
SSShiri Shinar
Shiri Shinar
Mesencephalosynapsis is characterized by a failure of the dorsal brainstem colliculi to separate into distinct lateral masses (non-cleavage, a.k.a. “fusion”). It is linked to ventriculomegaly and aqueductal stenosis but other associations have not been systematically examined. We reviewed a large cohort of fetal hydrocephalus cases to explore associations of aqueductal stenosis, mesencephalosynapsis, and other pathologies. Among 115 cases of fetal obstructive hydrocephalus (15-41 weeks gestation), mesencephalosynapsis was seen in 44 cases (38.3%). We graded the wide range of abnormal aqueductal histology; mesencephalosynapsis was associated with 67% of severe, 35% of mild, and 10% of borderline aqueductal pathologies. In 75% of cases, it was associated with other CNS anomalies, including rhombencephalosynapsis, holoprosencephaly, hemifacial microsomia, and amniotic rupture sequence. We also identified 2 cases of aqueductal stenosis associated with brainstem tegmental injury, probably ischemic in origin, without mesencephalosynapsis. Clinical and genetic associations of mesencephalosynapsis included diabetic embryopathy, amniotic rupture sequence, chromosomal abnormalities, and mutations in TBCD132, FRAS1, and NECTIN1. This is the largest review of the histology of fetal aqueductal stenosis to date. We conclude that mesencephalosynapsis points to a defect in embryonic brainstem patterning and may be isolated, associated with other malformations, and that it is found in heritable and non-heritable conditions.

7 July 2025 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
YFYael Fisher
Yael Fisher
OGOrli Greenberg
Orli Greenberg
PSPatrick Shannon
Patrick Shannon
ASAndrea Staines
Andrea Staines
BMBobbi McGivern
Bobbi McGivern
DCDavid Chitayat
David Chitayat
Neuroaxonal dystrophy (NAD) with osteopetrosis syndrome (OMIM # 600329) was first reported in a consanguineous Moroccan Jewish family. However, to date, no genetic variant has been linked to this disease. We report on sibs, born to consanguineous Pakistani parents identified prenatally with cerebral ventriculomegaly and agenesis of the corpus callosum, and autopsies done on both showed similar abnormalities, including facial dysmorphism, osteopetrosis, and neuropathologic findings consistent with NAD. Trio exome sequencing identified a homozygous c.283 C>T; p.(Arg95Ter) variant in exon 3 of the BORCS5 gene (NM_058169.4) in each of the couple's fetuses, and each of the parents was heterozygous for this variant. Interestingly, one of the affected fetuses was also homozygous for a biallelic missense VUS variant in SCYL2 (NM_017988.5) c.902G>A; p. Arg301His, heterozygous in parents. However, the autopsy findings on the two sibs were identical, raising the possibility that this SCYL2 homozygote variant did not contribute to the phenotype.

22 October 2026 in NEJM AI
Verified
Journal Article
Closed access
CBChen Buxbaum
Chen Buxbaum
ADAnat Yahav dovrat
Anat Yahav dovrat
YFYael Fisher
Yael Fisher
HZHaim Zilberman
Haim Zilberman
TSTali Siegal
Tali Siegal

5 March 2026 in Onco
Verified
Journal Article
Open access
PDF file
LOLiat Oren
Liat Oren
YFYael Fisher
Yael Fisher
OMOz Mordechai
Oz Mordechai
Background: DNA methylation profiling has become an important diagnostic tool in pediatric neuro-oncology, particularly for tumors with overlapping morphology or unusual immunophenotypes. Methods: We report four pediatric brain tumor cases evaluated by histopathology and immunohistochemistry, supplemented by targeted next-generation sequencing (NGS) and DNA methylation profiling using the DKFZ Brain Tumor Classifier (v12.8); one case also underwent DKFZ Sarcoma Classifier analysis (v13.2). Results: Methylation profiling provided clinically meaningful diagnostic insights across all cases. In two patients, methylation results supported integrated interpretation in diagnostically challenging settings without changing management. In two cases, methylation profiling prompted major diagnostic revisions with significant therapeutic consequences: (i) a tumor initially diagnosed as atypical teratoid/rhabdoid tumor was reclassified as CNS Ewing sarcoma, confirmed by an EWSR1-FLI1 fusion and immunophenotype, leading to a change to Ewing-based therapy; and (ii) a tumor interpreted as high-grade astrocytoma/glioblastoma was reclassified as a CNS tumor with BCOR internal tandem duplication, enabling a curative-intent approach and revised prognostic counseling. Conclusions: These cases illustrate that DNA methylation profiling can complement histopathology, resolve diagnostically ambiguous tumors, and in selected patients substantially alter treatment decisions and expected outcomes. Early integration of methylome profiling may improve precision diagnostics and reduce the risk of inappropriate therapy in pediatric brain tumors.